Introduction
Hepatic osteomalacia is a recognised complication of chronic cholestatic liver disease and may lead to severe bone pain and multiple fractures.' 3Until 1977 no consistently effective treatment for this condition had been described. Intravenous calcium gave temporary symptomatic relief of bone pain in patients with primary biliary cirrhosis (PBCj, but the amount of osteoid tissue seen on bone histology was reduced in only one patient.4 Parenteral vitamin D, treatment restores calcium-47 (4 7Ca) absorption and 25-hydroxy-vitamin D (25-OHD) concentrations to normal in PBC.5 6 In a series of 25 patients with cholestatic liver disease, 16 All four patients had generalised bone tenderness, and a radiological skeletal survey showed bone thinning but no evidence of osteitis fibrosa cystica or periosteal reactions. Patient 1 had had an intertrochanteric fracture of the right femur treated by pin and plate six months earlier. Patient 3 had fractured the right medial malleolus three years before and right femoral head two years earlier; skeletal survey showed partial collapse of the third and fourth lumbar vertebrae and a fracture of the eighth rib posteriorly. The fourth patient had fractured the left neck of femur, left tibia and fibula, and right radius and ulna within the previous nine months after two falls; radiology showed healing fractures. She also had Sudeck's atrophy of the left foot and collapse of multiple lumbothoracic vertebrae. Three patients (cases 2-4) had proximal muscle weakness, and in two (cases 2 and 3) myopathic changes were seen on electromyography.
1,25-(OH)2D3 was chemically synthesised, and ampoules of 15 ,ug in arachis oil were prepared under aseptic conditions. Every four weeks intramuscular injections of 15 jig 1,25-(OH)2D3 were given (except for the fourth patient, who once received 30 ,ig). 30 .tg intramuscularly; the plasma calcium rose to 315 mmol/l (12 6 mg/100 ml) on the third day, but fell to 2-83 mmol/l (11 3 mg/100 ml) the next day, after diuresis. No episodes of hypercalcaemia were seen, but plasma calcium tended to be higher by 0 13 mmol/l (0 5 mg/100 ml) to 0-25 mmol/l (1 0 mg/100 ml) the week after each injection of 15 sg 1,25-(OH)2D, and plasma phosphorus also rose by up to 0 31 mmol/l (1 0 mg/100 ml). Conversion: SI to traditiondW units-Plasma calcium: 1 mmol/l 4 mg/100 ml. Urinary calcium: 1 mmol 40 mg. Plasma phosphorus: 1 mmol/l 3-10 mg/100 ml. Plasma magnesium: 1 mmol/l z 2-43 mg/ 100 ml.
1,25-(OH),D, treatment, bone and muscle symptoms being particularly improved and the volume proportion of osteoid tissue visible on bone biopsy reduced. Plasma biochemical values and intestinal calcium and phosphorus absorption were either normal or only slightly disturbed at the start of the study; treatment resulted in only mild improvement of the plasma calcium values. Phosphate depletion might have contributed to the osteomalacia seen in these patients, but subnormal plasma phosphorus' values would be expected if it was a major factor. The lack of improvement in calcium and phosphorus absorption after 1,25-(OH)2D, may have been due to the timing of the test: one month after the previous injection, the 1,25-(OH)2D, may have been largely excreted. The post-treatment fall in urinary calcium excretion might have been caused by greater bone utilisation of calcium. In view of the initial normality and the minimal change in plasma biochemical values after treatment, the effects on bone and muscle might be attributed to a 
